Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin

A method for treating inflammation, the method comprising administering to a subject having inflammation a pharmaceutical composition comprising an isolated antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg10-Kallidin, but not to Bradykinin or des-Arg9-Bradykinin,

• wherein the antibody or antigen binding fragment comprises:
• i) a heavy chain variable domain comprising a heavy chain complementarity determining region 3 (HCDR3) amino acid sequence selected from the group consisting of:
• a) SEQ ID NO:
• 7 [X1Y-X2-X3D-X4HAM-X5Y], wherein
• X1 is Y, F or H,
• X2 is R, D, A, V, L, I, M, F, Y or W,
• X3 is Y, F, W or H,
• X4 is D, E or Y, and,
• X5 is D or E;
• b) SEQ ID NO:
• 63 [X1EYDGX2YX3X4LDX5], wherein
• X1 is W or F,
• X2 is N or no amino acid;
• X3 is Y or S,
• X4 is D or P, and
• X5 is F or Y;
• c) SEQ ID NO:
• 13;
• d) SEQ ID NO:
• 32;
• e) SEQ ID NO:
• 40;
• f) SEQ ID NO:
• 47;
• and
• g) SEQ ID NO:
• 55,
• ii) a heavy chain variable domain comprising a heavy chain complementarity determining region 2 (HCDR2) amino acid sequence selected from the group consisting of:
• h) SEQ ID NO:
• 8 [YFX1PX2NGNTGYNQKFRG], wherein
• X1 is D, R, A, V, L, I, M, F, Y or W, and
• X2 is Y, D, E, N, or Q;
• i) SEQ ID NO:
• 64 [WX1DPENGDX2X3YAPKFQG], wherein
• X1 is I, or V,
• X2 is T, or S, and
• X3 is G, or D;
• j) SEQ ID NO:
• 14
• k) SEQ ID NO:
• 33;
• l) SEQ ID NO:
• 41;
• m) SEQ ID NO:
• 48;
• and
• n) SEQ ID NO:
• 56,
• iii) a heavy chain variable domain comprising a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence selected from the group consisting of:
• o) SEQ ID NO:
• 9 [GYSFTDYX1IY], wherein X1 is N, W or Y;
• p) SEQ ID NO:
• 65 [GFNIKDYYX1H], wherein X1 is L, or M;
• q) SEQ ID NO:
• 15;
• r) SEQ ID NO:
• 34;
• s) SEQ ID NO:
• 42;
• t) SEQ ID NO:
• 49;
• and
• u) SEQ ID NO:
• 57,
• iv) a light chain variable domain comprising a light chain complementarity determining region 3 (LCDR3) amino acid sequence selected from the group consisting of:
• v) SEQ ID NO:
• 10 [QQ-X1 -X2S-X3P-X4T], wherein
• X1 is Y, F or H,
• X2 is Y, F, H or W,
• X3 is Y, F, T or H, and,
• X4 is W, Y, F, H or L;
• w) SEQ ID NO:
• 66 [QX1X2X3SX4PX5T], wherein
• X1 is Q or N,
• X2 is Y, F, D or H,
• X3 is Y, F, H or W,
• X4 is Y, F, T or H, and
• X5 is W, Y, F, H or L;
• x) SEQ ID NO:
• 69 [X1QGTHFPYT], wherein X1 is L or M;
• y) SEQ ID NO:
• 16;
• z) SEQ ID NO:
• 35;
• aa) SEQ ID NO:
• 43;
• bb) SEQ ID NO:
• 50;
• and
• cc) SEQ ID NO:
• 58, or
• v) a light chain variable domain comprising a light chain complementarity determining region 2 (LCDR2) amino acid sequence selected from the group consisting of:
• dd) SEQ ID NO:
• 11 [WASTRX1], wherein X1 is E, D, Q or N;
• ee) SEQ ID NO:
• 67 [X1ASTRX2], wherein
• X1 is W or G, and
• X2 is E, D, Q or N;
• ff) SEQ ID NO:
• 17;
• gg) SEQ ID NO:
• 36;
• hh) SEQ ID NO:
• 51;
• and
• ii) SEQ ID NO:
• 59, and
• vi) a light chain variable domain comprising a light chain complementarity determining region 1 (LCDR1) amino acid sequence selected from the group consisting of:
• jj) SEQ ID NO:
• 12 [KSSQSLL-X1SSNQKN-X2LA], wherein
• X1 is W, H, Y or F, and
• X2 is H or Y;
• kk) SEQ ID NO:
• 68 [KSSCISLLX1X2SX3QX4NX5LA], wherein
• X1 is W, H, Y or F,
• X2 is S or G,
• X3 is N or D,
• X4 is K or R, and
• X5 is H or Y;
• ll) SEQ ID NO:
• 70 [KSSQSLLYSNGX1TYLN], wherein X1 is K or E;
• mm) SEQ ID NO:
• 18;
• nn) SEQ ID NO:
• 37;
• oo) SEQ ID NO:
• 44;
• pp) SEQ ID NO:
• 52;
• and
• qq) SEQ ID NO:
• 60.